RXST Quote, Financials, Valuation and Earnings

Globus Medical has a net margin of -21.61% compared to RxSight's net margin of 12.62%. RxSight's return on equity of -10.39% beat Globus Medical's return on equity of 4.59%.

RxSight has a consensus price target of $21.18, signalling upside risk potential of 38.44%. On the other hand Globus Medical has an analysts' consensus of $85.17 which suggests that it could grow by 41.15%. Given that Globus Medical has higher upside potential than RxSight, analysts believe Globus Medical is more attractive than RxSight.

RxSight has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.202, suggesting its more volatile than the S&P 500 by 20.197%.

RxSight has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

RxSight quarterly revenues are $37.9M, which are smaller than Globus Medical quarterly revenues of $598.1M. RxSight's net income of -$8.2M is lower than Globus Medical's net income of $75.5M. Notably, RxSight's price-to-earnings ratio is -- while Globus Medical's PE ratio is 45.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight is 4.10x versus 3.33x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Integra Lifesciences Holdings has a net margin of -21.61% compared to RxSight's net margin of -6.61%. RxSight's return on equity of -10.39% beat Integra Lifesciences Holdings's return on equity of -1.88%.

RxSight has a consensus price target of $21.18, signalling upside risk potential of 38.44%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $16.13 which suggests that it could grow by 16.17%. Given that RxSight has higher upside potential than Integra Lifesciences Holdings, analysts believe RxSight is more attractive than Integra Lifesciences Holdings.

RxSight has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.164, suggesting its more volatile than the S&P 500 by 16.396%.

RxSight has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight pays -- of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend.

RxSight quarterly revenues are $37.9M, which are smaller than Integra Lifesciences Holdings quarterly revenues of $382.7M. RxSight's net income of -$8.2M is higher than Integra Lifesciences Holdings's net income of -$25.3M. Notably, RxSight's price-to-earnings ratio is -- while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight is 4.10x versus 0.66x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -21.61% compared to RxSight's net margin of 6.22%. RxSight's return on equity of -10.39% beat Insulet's return on equity of 36.9%.

RxSight has a consensus price target of $21.18, signalling upside risk potential of 38.44%. On the other hand Insulet has an analysts' consensus of $334.74 which suggests that it could grow by 9.52%. Given that RxSight has higher upside potential than Insulet, analysts believe RxSight is more attractive than Insulet.

RxSight has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insulet has a beta of 1.375, suggesting its more volatile than the S&P 500 by 37.475%.

RxSight has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

RxSight quarterly revenues are $37.9M, which are smaller than Insulet quarterly revenues of $569M. RxSight's net income of -$8.2M is lower than Insulet's net income of $35.4M. Notably, RxSight's price-to-earnings ratio is -- while Insulet's PE ratio is 54.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight is 4.10x versus 10.28x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Treace Medical Concepts has a net margin of -21.61% compared to RxSight's net margin of -30.29%. RxSight's return on equity of -10.39% beat Treace Medical Concepts's return on equity of -47.17%.

RxSight has a consensus price target of $21.18, signalling upside risk potential of 38.44%. On the other hand Treace Medical Concepts has an analysts' consensus of $9.73 which suggests that it could grow by 64.89%. Given that Treace Medical Concepts has higher upside potential than RxSight, analysts believe Treace Medical Concepts is more attractive than RxSight.

RxSight has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Treace Medical Concepts has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

RxSight has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Treace Medical Concepts offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight pays -- of its earnings as a dividend. Treace Medical Concepts pays out -- of its earnings as a dividend.

RxSight quarterly revenues are $37.9M, which are smaller than Treace Medical Concepts quarterly revenues of $52.6M. RxSight's net income of -$8.2M is higher than Treace Medical Concepts's net income of -$15.9M. Notably, RxSight's price-to-earnings ratio is -- while Treace Medical Concepts's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight is 4.10x versus 1.74x for Treace Medical Concepts. Usually stocks with elevated PS ratios are considered overvalued.